MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414289 | Name: NBI6024

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NBI6024 is an altered-peptide ligand, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. It is used for the treatment of autoimmune diseases.

Chemical Structure

NBI6024
NBI6024
CAS#239480-61-6

Theoretical Analysis

MedKoo Cat#: 414289

Name: NBI6024

CAS#: 239480-61-6

Chemical Formula: C66H112N20O21

Exact Mass: 1520.8311

Molecular Weight: 1521.74

Elemental Analysis: C, 52.09; H, 7.42; N, 18.41; O, 22.08

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
NBI6024; NBI-6024; NBI 6024
IUPAC/Chemical Name
(5S,8S,14S,17S,20S,23S,26S,29S,32S)-32-((S)-2-((S)-2-((S)-2-((S)-2-amino-3-hydroxypropanamido)-3-(1H-imidazol-4-yl)propanamido)-4-methylpentanamido)-3-methylbutanamido)-8-(2-carboxyethyl)-5-(3-guanidinopropyl)-20,26-diisobutyl-17-isopropyl-14,23,29-trimethyl-4,7,10,13,16,19,22,25,28,31-decaoxo-3,6,9,12,15,18,21,24,27,30-decaazapentatriacontanedioic acid
InChi Key
PHEWVCZHSBTZFX-DBCSJUPNSA-N
InChi Code
InChI=1S/C66H112N20O21/c1-30(2)21-43(81-54(96)36(12)75-58(100)42(17-19-49(91)92)80-65(107)52(34(9)10)86-63(105)45(23-32(5)6)84-61(103)46(24-38-25-70-29-74-38)83-56(98)39(67)28-87)60(102)76-37(13)55(97)82-44(22-31(3)4)62(104)85-51(33(7)8)64(106)77-35(11)53(95)72-26-47(88)78-41(16-18-48(89)90)59(101)79-40(15-14-20-71-66(68)69)57(99)73-27-50(93)94/h25,29-37,39-46,51-52,87H,14-24,26-28,67H2,1-13H3,(H,70,74)(H,72,95)(H,73,99)(H,75,100)(H,76,102)(H,77,106)(H,78,88)(H,79,101)(H,80,107)(H,81,96)(H,82,97)(H,83,98)(H,84,103)(H,85,104)(H,86,105)(H,89,90)(H,91,92)(H,93,94)(H4,68,69,71)/t35-,36-,37-,39-,40-,41-,42-,43-,44-,45-,46-,51-,52-/m0/s1 Download
SMILES Code
CC(C[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(NCC(O)=O)=O)CCCNC(N)=N)=O)CCC(O)=O)=O)=O)C)=O)C(C)C)=O)CC(C)C)=O)C)=O)NC([C@@H](NC([C@@H](NC([C@H](C(C)C)NC([C@@H](NC([C@@H](NC([C@H](CO)N)=O)Cc1nc[nH]c1)=O)CC(C)C)=O)=O)CCC(O)=O)=O)C)=O)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,521.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Maruyama T. [Pharmacotherapies for type 1 diabetes mellitus]. Nihon Rinsho. 2002 Sep;60 Suppl 9:190-5. Japanese. PMID: 12386992. 2: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002 Oct;24(8):525-51. PMID: 12500432. 3: Giannoukakis N. NBI-6024 (Neurocrine Biosciences). IDrugs. 2002 Dec;5(12):1162-7. PMID: 12800057. 4: Alleva DG, Maki RA, Putnam AL, Robinson JM, Kipnes MS, Dandona P, Marks JB, Simmons DL, Greenbaum CJ, Jimenez RG, Conlon PJ, Gottlieb PA. Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand J Immunol. 2006 Jan;63(1):59-69. doi: 10.1111/j.1365-3083.2005.01705.x. PMID: 16398702. 5: Walter M, Philotheou A, Bonnici F, Ziegler AG, Jimenez R; NBI-6024 Study Group. No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care. 2009 Nov;32(11):2036-40. doi: 10.2337/dc09-0449. Epub 2009 Aug 18. PMID: 19690081; PMCID: PMC2768201. 6: Alleva DG, Gaur A, Jin L, Wegmann D, Gottlieb PA, Pahuja A, Johnson EB, Motheral T, Putnam A, Crowe PD, Ling N, Boehme SA, Conlon PJ. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes. 2002 Jul;51(7):2126-34. doi: 10.2337/diabetes.51.7.2126. PMID: 12086942.